Lillian Yuen-Ho

Lillian Yuen-Ho asked about the importance of being first to pivotal data for INHBE, whether the Activin E space can accommodate multiple players, and what differentiating factors will distinguish therapies in this class.

Answer

President and CEO Paul B. Bolno acknowledged that the large obesity market can accommodate multiple companies, but emphasized the advantage of being a leader. He asserted that Wave is well-positioned to lead INHBE silencing due to its highly differentiated SpiNA chemistry, which has shown single-dose weight loss in preclinical studies and translated into differentiated clinical data. Bolno noted that other INHBE programs appear similar, suggesting Wave's once-to-twice-a-year therapy will uniquely define the space. He highlighted that WVE-007's efficacy is already observed in low BMI, non-diabetic patients, which will only be further built upon with higher doses and in patients with higher BMI and comorbidities.

Lillian Yuen-Ho asked about the importance of being first to pivotal data for INHBE, whether the Activin E space can accommodate multiple players, and the differentiating factors among Activin E lowering therapies.

Answer

Paul Bolno, President and CEO, acknowledged that the large obesity market can accommodate multiple companies but believes Wave is well-positioned to be the leader for INHBE silencing due to its highly differentiated SpiNA chemistry. He noted that Wave's preclinical data, showing dramatic and sustained Activin E reduction tied to weight loss, has translated into a highly differentiated clinical profile (once-to-twice-a-year therapy, efficacy in low BMI/non-diabetic patients). Bolno expects this differentiation to define the space and sustain Wave's leadership, with further data from higher BMI cohorts expected to build on current efficacy.